Improved genome editing with Cas12a and Cas9 chRDNA platform in T, NK, B, andiPS cells Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®.February 21-24,2024. High-specificity CRISPR-mediated genome engineering inanti-BCMAallogeneicCAR T cellssuppresses allograft rejection in ...
Eidell, K.P., Hemann, M.T. FAS-less allogeneic CAR T cells. Nat. Biomed. Eng 8, 1518–1520 (2024). https://doi.org/10.1038/s41551-024-01319-y Download citation Published20 December 2024 Issue DateDecember 2024 DOIhttps://doi.org/10.1038/s41551-024-01319-y Springer Nature Limited ...
CAR-T cells prepared from allogeneic sources (allo-CAR-Ts) can be an alternative option to overcome these obstacles. Recently, several allo-CAR-Ts have entered into the early clinical trials. Despite their promising preclinical and clinical results, there are two main barriers, including graft-...
Eidell, K.P., Hemann, M.T.FAS-less allogeneic CAR T cells.Nat. Biomed. Eng8, 1518–1520 (2024). https://doi.org/10.1038/s41551-024-01319-y Download citation Published20 December 2024 Issue DateDecember 2024 DOIhttps://doi.org/10.1038/s41551-024-01319-y ...
The allogeneic BCMA-targeted CAR T-cell therapy P-BCMA-ALLO1 led to high response rates in heavily pretreated patients with relapsed/refractory multiple myeloma. Patients given the regimen were also able to skip invasive apheresis, bridging therapy, and manufacturing delays, per data from...
Autologous chimeric antigen receptor (CAR) T cells have changed the therapeutic landscape in haematological malignancies. Nevertheless, the use of allogeneic CAR T cells from donors has many potential advantages over autologous approaches, such as the im
DISCOVER ATARA Atara is an allogeneic T-cell immunotherapy company. We're harnessing the natural biology of T cells—our body’s most effective weapon in fighting disease—to develop transformative therapies for patients with cancer and autoimmune conditions. ...
Abstract 3184: Targeting multiple solid tumor types with anti-CD70 allogeneic CAR-T cells doi:10.1158/1538-7445.AM2019-3184CD70 (CD27 ligand) is highly expressed in multiple hematologic malignancies, such as non-Hodgkin lymphoma, multiple myeloma, and chronic lymphocytic leukemia, and is uniquely...
Difference is Autologous CAR T-cell therapy uses a patient's immune cells while Allogeneic CAR T-cell therapy uses donor T cells or umbilical cord...
Although chimeric antigen receptor T (CAR-T) cells have been proven to be an effective way of treating B cell malignancies, a lot of patients could not ben